Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03734-8 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Javier Puente und 13 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Ca…. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Health Resources, Patient Acceptance of Health Care, Practice Patterns, Physicians'. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma, Inc., Seagen.
Abstract (Originalsprache)
Purpose
Real-world evidence on locally advanced or metastatic urothelial carcinoma (la/mUC) management in Spain is limited. This study describes patient characteristics, treatment patterns, survival, and health care resource utilization (HCRU) in this population. Methods/patients This retrospective observational study included all adults with a first diagnosis/record of la/mUC (index date) from January 2015 to June 2020 at nine university hospitals in Spain. Data were collected up to December 31, 2020 (end of study), death, or loss to follow-up. Patient characteristics, treatment patterns, median overall survival (OS) and progression-free survival (PFS) from index date (Kaplan–Meier estimates), and disease-specific HCRU were described.
Results
Among 829 patients, median age at diagnosis was 71 years; 70.2% had ≥ 1 comorbidity, and 52.5% were eligible for cisplatin. Median follow-up was 12.7 months. Most (84.7%) patients received first-line systemic treatment; of these, 46.9% ( n = 329) received second-line and 16.6% ( n = 116) received third-line therapy. Chemotherapy was the most common treatment in all lines of therapy, followed by programmed cell death protein 1/ligand 1 inhibitors. Median (95% confidence interval) OS and PFS were 18.8 (17.5–21.5) and 9.9 (8.9–10.5) months, respectively. Most patients required ≥ 1 outpatient visit (71.8%), inpatient admission (56.6%), or emergency department visit (56.5%).
Conclusions
Therapeutic patterns were consistent with Spanish guideline recommendations. Chemotherapy had a role in first-line treatment of la/mUC in Spain during the study period. However, the disease burden remains high, and new first-line treatments recommended in the latest European guidelines should be made available to patients in Spain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain. javierpuente.hcs…
- Servicio de Oncología Médica, Hospital Universitario La Paz, Madrid, Spain.
- Medical Oncology Department, Maimonides Institute for Biomedical Research of Córdoba (IMIBIC) Hospital Universitario Reina Sofía, Cordoba, Spain.
- Institut Català d'Oncologia, IDIBELL. University of Barcelona, Barcelona, Spain.
- Servicio de Oncología Médica, Hospital de La Santa Creu i Sant Pau, Barcelona, Spain.
- Servicio de Oncología Médica, Hospital Universitario Lucus Augusti, Lugo, Spain.
Förderung
- Astellas Pharma, Inc.
- Seagen
Zitieren
APA
Puente, J., Pinto, A., Mendez-Vidal, M. J., García Del Muro, X., Maroto, P., Vazquez, S., Luque-Caro, R., Anido, U., Strunz-McKendry, T., Upadhyay, A., Montes, J., Ortiz Nuñez, A., González Portela, J., & Castellano, D. (2024). Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03734-8
Vancouver
Puente J, Pinto A, Mendez-Vidal MJ, García Del Muro X, Maroto P, Vazquez S, et al. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03734-8
BibTeX
@article{Puente2024,
author = {Puente, Javier and Pinto, Alvaro and Mendez-Vidal, Maria José and García Del Muro, Xavier and Maroto, Pablo and Vazquez, Sergio and Luque-Caro, Raquel and Anido, Urbano and Strunz-McKendry, Torsten and Upadhyay, Anil and Montes, Jose and Ortiz Nuñez, Aurora and González Portela, Judit and Castellano, Daniel},
title = {Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03734-8}
}
EUVIMED